Morgan Stanley Maintains Equal-Weight on InterMune

Morgan Stanley is out with its report today on InterMune (NASDAQ: ITMN), maintaining Equal-weight.

In its report, Morgan Stanley writes, "We attended the recent European Respiratory Society meeting which hosted the initial symposia supporting the new German launch of Esbriet (pirfenidone) in IPF. Our takeaways are below, with our bias being more positive than in the past on the ultimate potential of Esbriet."

At the time of posting, shares of ITMN were trading pre-market at $22.25, up 2.39% from Wednesday's close.